Navigation Links
Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
Date:4/24/2013

SUNNYVALE, Calif., April 24, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today announced that it will report financial results and recent developments for its three months ended March 31, 2013 after the NASDAQ Market closes on Wednesday, May 1, 2013.  The Company will conduct a conference call and audio webcast at 4:30 p.m ET on the same day. As previously announced, the Company changed its fiscal year end from June 30 to December 31, effective December 31, 2012. As a result, the three months ended March 31, 2013 represents the Company's fiscal 2013 first quarter.

Conference call and webcast details:

Date: May 1, 2013
Time: 4:30 PM ET
Listen via Internet: http://ir.pharmacyclics.com/events.cfm
Toll-free: (877)-407-0778
International: (201)-689-8565

Replay Number (Toll Free): (877)-660-6853
Replay Number (International): (201)-612-7415
Conference ID #: 413317

A webcast replay will be available on the Pharmacyclics website for 30 days.

About Pharmacyclics
Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs; and to identify promising product candidates based on scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has three product candidates in clinical de
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
2. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
3. Pharmacyclics, Inc. Prices Public Offering of Common Stock
4. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
5. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
6. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
7. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
8. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
9. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
10. Immunomic Therapeutics Announces Interim Data Analysis of Phase I Study to Treat Japanese Red Cedar Allergy
11. Anterios, Inc., Announces Corporate Financing To Further Clinical Development Of Its Topical Botulinum Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/vt6973/mems_gyroscopes ... "MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... made a lot of progress in the past ... now accepted in high-reliability environments, and are even ...
(Date:12/15/2014)... 2014 Research and Markets , ... ) has announced the addition of the "Cardiac ... to their offering. Global Guidewires sector is projected ... North America accounts for nearly 35% (2015) ... claims approximately 25% (2018). Asia-Pacific ...
(Date:12/15/2014)... 2014  Inovio Pharmaceuticals, Inc. (NASDAQ: ... to the NASDAQ Biotechnology Index (NBI). The addition ... upon market open on December 22, 2014. ... track the performance of a set of NASDAQ-listed ... pharmaceutical according to the Industry Classification Benchmark. The ...
Breaking Medicine Technology:MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 3Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 4Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 2Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 3Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 4
(Date:12/19/2014)... Slone Partners , a national recruitment firm ... and laboratory testing industries, has promoted Leslie Loveless ... announcement comes after a year of expansion by ... Boston and several new additions to the team. ... experience," said Adam Slone, Chief Executive Officer. “Diagnostics ...
(Date:12/19/2014)... Dec. 18, 2014 (HealthDay News) -- Being in good shape ... report. They looked at data from more than 57,000 ... underwent treadmill tests between 1991 and 2009. Those in ... of having high blood pressure at the start of the ... high levels of fitness. Of the more than 8,000 ...
(Date:12/19/2014)... (HealthDay News) -- Traveling through the same U.S. airport ... three others within a four-hour time span, illustrating just ... shows. "The exposures in this report were not ... international terminal, highlighting the fact that measles is highly ... infectious disease specialist at the U.S. Centers for Disease ...
(Date:12/17/2014)... Mass. (PRWEB) December 17, 2014 ... of Osteopathic Medicine (ACOM), which welcomed its inaugural ... Desktop Infrastructure (VDI) to seamlessly support bring your ... – and teaching – experience. The solution, comprised ... NetScaler , Dell server and storage infrastructure ...
(Date:12/17/2014)... Miami, FL (PRWEB) December 17, 2014 ... has not been able to eradicate the head louse ... and hassle for parents. Each year between six and ... Lice Troopers, the Miami-based lice removal treatment company comes ... safe, non-toxic and environmentally friendly. With its track record ...
Breaking Medicine News(10 mins):Health News:Slone Partners Promotes Leslie Loveless to Chief Operating Officer 2Health News:Being Fit Keeps Blood Pressure in Check 2Health News:Arriving Now at Gate 42: Measles 2Health News:Arriving Now at Gate 42: Measles 3Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 3Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2
... Sichuan University in Chengdu, China, investigated eye movements in Chinese ... that control them and how they compare between different human ... that is rare in British people, is much more common ... in brain function between different populations. Tests ...
... Reporter , WEDNESDAY, March 23 (HealthDay News) -- Though ... babies, Americans, level of exposure to mercury from sources ... risk of heart disease, stroke or other cardiovascular disease, ... research that produced inconsistent results, scientists from Harvard School ...
... survey of over 9,000 people in seven different countries across Europe ... of life in the time they had left, rather than extend ... illnesses such as cancer, and issues raised when caring for a ... The research was carried out as part of an EU-funded project ...
... By Serena Gordon HealthDay Reporter , WEDNESDAY, ... the diabetes drug Actos helped people who had prediabetes ... extremely effective in preventing diabetes," said study author Dr. ... and chief of the diabetes division at the University ...
... Boston (March 23, 2011) A paper, "Association of ... Cardiac Events," published in the March 23/30 issue of ... research done by Tufts Clinical and Translational Science ... Issa J. Dahabreh, MD. This paper was also developed ...
... March 23 (HealthDay News) -- The risk of lung cancer ... that of those who prefer regular cigarettes, researchers report. ... Administration advisory panel that made headlines Friday when it said ... While the panel concluded that menthols, minty flavor seems to ...
Cached Medicine News:Health News:Eye movement differs in British and Chinese populations 2Health News:Americans' Exposure to Mercury From Fish Won't Harm Hearts: Study 2Health News:Americans' Exposure to Mercury From Fish Won't Harm Hearts: Study 3Health News:Europe-wide survey reveals priorities for end-of-life care 2Health News:Europe-wide survey reveals priorities for end-of-life care 3Health News:Actos Cut Risk of Prediabetes Becoming Diabetes in Study 2Health News:Actos Cut Risk of Prediabetes Becoming Diabetes in Study 3Health News:Tufts paper assesses effect of episodic sexual/physical activity on cardiac events 2Health News:Tufts paper assesses effect of episodic sexual/physical activity on cardiac events 3Health News:Menthol Cigarettes Pose No Added Lung Cancer Risk: Study 2
... is one of the world's ... with a 7 F introducer, ... is designed to lower the ... allow introduction in smaller, more ...
Tendril DX active-fixation leads allows for lower thresholds initially and during the lead maturation phase....
... Guidant Flextend lead is ... lead with an extendable/retractable ... helix design offers various ... permanent implantation in the ...
... is a low profile implantable bipolar ... stimulation of either the atrium or ... supplied with a screwdriver shape stylet ... lead. The ring tip and fixation ...
Medicine Products: